"ECG Buddy-LVD" uses 12-lead ECG analysis to help identify LVEF of 40% or less
External validation using more than 22,000 MIMIC-IV cases... Plans adoption with U.S. healthcare facilities and local partners

Image created by Claude

Image created by Claude

View original image

Patients with reduced heart-pumping function are at high risk of developing severe heart conditions, including heart failure. An echocardiogram is needed to assess this accurately, but it cannot be performed immediately at every healthcare facility because it requires specialized equipment and trained personnel. A Korean technology that aims to bridge this gap by using AI to analyze electrocardiograms, which can be measured quickly and easily at any healthcare facility, has received clearance from the U.S. Food and Drug Administration (FDA).


Medical AI company ARPI (CEO Kim Junghee) announced that its AI electrocardiogram analysis software, ECG Buddy-LVD (model EB-LVD-01), has received FDA 510(k) clearance. Following a 510(k) review, the FDA determined on November 6, local time, that ECG Buddy-LVD is “substantially equivalent” to a legally marketed device. A 510(k) is a premarket notification procedure through which the FDA determines whether a device is substantially equivalent to a device already legally on the market.


ECG Buddy-LVD is software as a medical device that analyzes 12-lead electrocardiograms using AI to identify findings associated with a reduced left ventricular ejection fraction (LVEF) of 40% or less. LVEF is the proportion of blood ejected from the left ventricle each time the heart contracts and is a key indicator of the heart’s pumping function. The product provides information to help healthcare professionals identify patients with suspected reduced heart function at an early stage and consider necessary follow-up tests. The company says the software is not a substitute for diagnosis, but rather a tool to support healthcare professionals’ decision-making.


ARPI’s electrocardiogram-based technology for assessing left ventricular function has undergone repeated validation in international academic journals. In one notable study, an external validation study analyzing more than 22,000 patient cases from MIMIC-IV, a large public medical database in the United States, was published in Clinical and Experimental Emergency Medicine in 2025. More than 22 studies related to ECG Buddy have been published in international academic journals to date.


ARPI has also continued to build a track record in Korea and abroad. In January 2024, the company obtained approval from the Ministry of Food and Drug Safety for ECG Buddy as a Class II medical device, now classified as a digital medical device. It has since secured major overseas approvals and registrations, including CE marking under the European Union’s Medical Device Regulation (EU MDR 2017/745), listing on Australia’s ARTG, and approvals or registrations from Taiwan’s TFDA, Vietnam, New Zealand, and Saudi Arabia’s SFDA. In Korea, more than 150 healthcare facilities have adopted ECG Buddy, which analyzes over 300,000 electrocardiograms a month. ECG Buddy Clinic won the grand prize at the Korean Society of Heart Failure’s Digital Health Research Group’s “2026 Digital Health Innovation Award” in February 2026, followed by the Innovation Award at K-HOSPITAL FAIR 2026 in August of the same year. With this clearance, ARPI has laid the groundwork for entering the U.S. market. The company plans to work with U.S. healthcare facilities and local partners to promote the adoption of ECG Buddy-LVD.


The AI electrocardiogram market is expected to grow rapidly in the coming years, particularly in the United States, as specialized technologies can ease bottlenecks in healthcare and improve patient outcomes.


“This FDA 510(k) clearance means ECG Buddy has passed the first gateway to entering the U.S. market,” said CEO Kim Junghee. “Our goal is to help healthcare professionals identify patients who may have reduced left ventricular function by using electrocardiograms, one of the most widely available tests. We will steadily demonstrate its value in U.S. healthcare settings as well.”



ECG Buddy-LVD’s strength lies in expanding the use of electrocardiograms, which are already widely used in clinical settings, rather than adding new equipment or tests. Even when an echocardiogram cannot be performed immediately, the software can help identify patients who may have reduced left ventricular function and support healthcare professionals in considering follow-up tests. It is therefore a meaningful aid in helping ensure that patients at risk of heart disease are not overlooked. Having secured FDA 510(k) clearance on the strength of its use at more than 150 healthcare facilities in Korea and validation in international academic journals, ARPI is now preparing to demonstrate the product’s value in U.S. healthcare settings.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing